Skip to main content


19-06-2018 | Kidney cancer | Highlight | Article

ASCO 2018

Need for nephrectomy challenged in some sunitinib-treated metastatic renal cancers

Results of the phase III CARMENA trial show that treatment with sunitinib alone is as good as treatment with nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic renal cell carcinoma.


ASCO Annual Meeting 2018; Chicago, Illinois, USA, N Engl J Med 2018; Advance online publication

ASCO 2018: Abi Race trial in prostate cancer

Lead author Daniel George discusses his team's findings of a greater and longer lasting treatment effect with abiraterone acetate and prednisone in Black than White men with metastatic castration-resistance prostate cancer (3:59). 

ASCO 2018: CARMENA trial in renal cell carcinoma

Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).

ASCO 2018: TAILORx trial in breast cancer

Joseph Sparano gives an overview of his team's findings regarding a 21-gene prognostic test that could help tailor treatment for women with early breast cancer (3:24).

ASCO 2018: IMPACT trial across multiple cancers

Apostolia Tsimberidou discusses the findings of the IMPACT study, looking at the survival benefits of matching targeted treatments to the genetic alterations of tumors across multiple cancer types (7:56).

22-06-2018 | ASCO | Main feed | News

ASCO 2018 in brief

Avelumab–lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC

The JAVELIN Lung 101 study suggests that the PD-L1 inhibitor avelumab plus the third-generation ALK inhibitor lorlatinib may be a feasible combination in non-small-cell lung cancer patients with heavily pretreated, advanced ALK-positive disease.


ASCO Annual Meeting 2018; Chicago, Illinois, USA

22-06-2018 | Breast cancer | News | Article

Mixed results for denosumab for the prevention of breast cancer recurrence

Two opposing sets of phase III results regarding the effect of denosumab on the recurrence of hormone receptor-positive nonmetastatic breast cancer have been presented at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.


ASCO Annual Meeting 2018; Chicago, Illinois, USA

21-06-2018 | ASCO | Main feed | News

ASCO 2018 in brief

Maintenance therapy boosts high-risk pediatric rhabdomyosarcoma survival

A significant overall survival benefit with the use of maintenance chemotherapy has been demonstrated by the RMS2005 trial of children who have completed standard treatment for high-risk, nonmetastatic rhabdomyosarcoma.

20-06-2018 | Non-small-cell lung cancer | News | Article

ASCO 2018

Atezolizumab boosts survival in metastatic nonsquamous NSCLC

Adding atezolizumab to bevacizumab plus chemotherapy significantly delays disease progression and death among chemotherapy-naïve patients with metastatic nonsquamous non-small-cell lung cancer, phase III study data show.


ASCO Annual Meeting 2018; Chicago, Illinois, USA, N Engl J Med 2018; 378: 2288–2301

Chronic Kidney Disease Patients Increasingly Excluded From Cancer Trials

The majority of trials testing drugs for breast, bladder, colorectal, lung and prostate cancer between 2012 and 2017 excluded patients on the basis of chronic kidney disease biomarkers Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

Twitter Icon Follow medwireNews

Click here
image credits